Sameer E. Al-harthy, Mashael S. Al-Motairi, Huda M. Al-Kreathy, Fatemah O. Kamel, Mohamed M. Sayed-Ahmed, Etimad Abbas Huwait, Hamdan S. Al-Malkey & Abdel-Moneim M. Osman·Journal of Pharmaceutical Research International·2019
Background: Worldwide, breast cancer is a main cause of morbidity and mortality in females. Doxorubicin (DOX) is an anthracycline anticancer drug and most commonly employed in polychemotherapy protocols in the treatment of solid and hematological tumors. Unfortunately, its optima...
Open access
Research Article10.9734/jpri/2019/v27i630188
Aims: In numerous cases, patients with inflammatory bowel diseases (IBDs) are refractory to standard treatment. Sirolimus (SIR) and tacrolimus (TAC) are immunosuppressant drugs with encouraging outcomes. However, they have side effects causing limitations in their use. Metformin...
Open access
Research Article10.9734/jpri/2020/v32i1030496
Ali A. AlQahtani, Abdel-Moneim M. Osman, Zoheir A. Damanhouri, Huda M. Al-Kreathy, Hamdan S. Al-Malky, Wafaa S. Ramadan, Sameer E. Alharthi & Fatemah O. Kamel·Journal of Pharmaceutical Research International·2019
Background: Doxorubicin (DOX) is an effective antineoplastic drug indicated to treat many cancerous diseases but its clinical usefulness is limited by many side effects. The main and the most serious one is DOX induced cardiotoxicity. Many strategies have been tried to minimize t...
Open access
Research Article10.9734/jpri/2019/v27i330170